The Joint Committee on Vaccination and Immunisation (JCVI) does not recommend the introduction of a routine immunisation programme offering pneumococcal conjugate vaccine to all clinical risk groups and older patients for invasive pneumococcal disease (IPD).
Some clinical risk groups e.g. those who are clinically severely immunocompromised and have a particularly elevated risk of, and high mortality from, IPD may benefit from immunisation with the 13-valent pneumococcal conjugate vaccine PCV13 in the short-term.
In the meantime, the Committee advises that those aged two to less than 65 years in the other clinical risk groups and all those aged 65 years and older should continue to be offered 23-valent pneumococcal polysaccharide vaccine (PPV23) as currently advised.